MYCN contributes to the sensitization of acute myelogenous leukemia cells to cisplatin by targeting SRY-box transcription factor 4

Little was known about the role of MYCN in drug resistance in acute myeloid leukemia (AML). We investigated impacts of MYCN on sensitization of AML cell to cisplatin, and its interaction with SRY-box transcription factor 4 (SOX4). In vitro, human AML cell lines HL60 and KG-1 were transfected with th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xianbao Huang, Ling Qi, Wei Lu, Ziye Li, Wuping Li, Fei Li
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	mycn sry-box transcription factor 4 cisplatin acute myeloid leukemia apoptosis Biotechnology TP248.13-248.65
Acceso en línea:	https://doaj.org/article/f5f9fcbfe37a41d894aea6a42f012166
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f5f9fcbfe37a41d894aea6a42f012166
record_format	dspace
spelling	oai:doaj.org-article:f5f9fcbfe37a41d894aea6a42f0121662021-11-04T15:51:54ZMYCN contributes to the sensitization of acute myelogenous leukemia cells to cisplatin by targeting SRY-box transcription factor 42165-59792165-598710.1080/21655979.2021.1997697https://doaj.org/article/f5f9fcbfe37a41d894aea6a42f0121662021-10-01T00:00:00Zhttp://dx.doi.org/10.1080/21655979.2021.1997697https://doaj.org/toc/2165-5979https://doaj.org/toc/2165-5987Little was known about the role of MYCN in drug resistance in acute myeloid leukemia (AML). We investigated impacts of MYCN on sensitization of AML cell to cisplatin, and its interaction with SRY-box transcription factor 4 (SOX4). In vitro, human AML cell lines HL60 and KG-1 were transfected with the overexpression plasmids and specific small interfering RNA of MYCN (siMYCN), or siSOX4, and then treated with 2 μg/mL cisplatin. MTT and flow cytometry assays were performed to estimate the viability and apoptosis of AML cell. The expressions of MYCN and SOX4 in AML patients and the associations between these two were analyzed by bioinformatics analysis, luciferase assay and quantitative reverse transcription polymerase chain reaction (qRT-PCR). In vivo, transfected HL60 cells were injected into BALB/c nude mice. The tumor size and weight were recorded, and the expressions of MYCN and SOX4 were determined with immunohistochemistry. MYCY and SOX4 were highly-expressed in AML, and their expressions were positively correlated. In AML cells, the treatment using cisplatin induced higher MYCN expression and augmented apoptosis, whereas decreasing the viability. Silencing of MYCN enhanced the tumor-suppressive effects of cisplatin on AML by decreasing cell viability and increasing apoptosis. The promoter of SOX4 was targeted by MYCN. Lower cell viability and higher apoptosis rate were seen in AML cells transfected with siSOX4, the effects of which were partially reversed by overexpressed MYCN. Silencing of MYCN retarded the tumor growth and SOX4 expression in tumor in vivo. Collectively, MYCN sensitized AML cells to cisplatin by targeting SOX4.Xianbao HuangLing QiWei LuZiye LiWuping LiFei LiTaylor & Francis Grouparticlemycnsry-box transcription factor 4cisplatinacute myeloid leukemiaapoptosisBiotechnologyTP248.13-248.65ENBioengineered, Vol 0, Iss 0 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	mycn sry-box transcription factor 4 cisplatin acute myeloid leukemia apoptosis Biotechnology TP248.13-248.65
spellingShingle	mycn sry-box transcription factor 4 cisplatin acute myeloid leukemia apoptosis Biotechnology TP248.13-248.65 Xianbao Huang Ling Qi Wei Lu Ziye Li Wuping Li Fei Li MYCN contributes to the sensitization of acute myelogenous leukemia cells to cisplatin by targeting SRY-box transcription factor 4
description	Little was known about the role of MYCN in drug resistance in acute myeloid leukemia (AML). We investigated impacts of MYCN on sensitization of AML cell to cisplatin, and its interaction with SRY-box transcription factor 4 (SOX4). In vitro, human AML cell lines HL60 and KG-1 were transfected with the overexpression plasmids and specific small interfering RNA of MYCN (siMYCN), or siSOX4, and then treated with 2 μg/mL cisplatin. MTT and flow cytometry assays were performed to estimate the viability and apoptosis of AML cell. The expressions of MYCN and SOX4 in AML patients and the associations between these two were analyzed by bioinformatics analysis, luciferase assay and quantitative reverse transcription polymerase chain reaction (qRT-PCR). In vivo, transfected HL60 cells were injected into BALB/c nude mice. The tumor size and weight were recorded, and the expressions of MYCN and SOX4 were determined with immunohistochemistry. MYCY and SOX4 were highly-expressed in AML, and their expressions were positively correlated. In AML cells, the treatment using cisplatin induced higher MYCN expression and augmented apoptosis, whereas decreasing the viability. Silencing of MYCN enhanced the tumor-suppressive effects of cisplatin on AML by decreasing cell viability and increasing apoptosis. The promoter of SOX4 was targeted by MYCN. Lower cell viability and higher apoptosis rate were seen in AML cells transfected with siSOX4, the effects of which were partially reversed by overexpressed MYCN. Silencing of MYCN retarded the tumor growth and SOX4 expression in tumor in vivo. Collectively, MYCN sensitized AML cells to cisplatin by targeting SOX4.
format	article
author	Xianbao Huang Ling Qi Wei Lu Ziye Li Wuping Li Fei Li
author_facet	Xianbao Huang Ling Qi Wei Lu Ziye Li Wuping Li Fei Li
author_sort	Xianbao Huang
title	MYCN contributes to the sensitization of acute myelogenous leukemia cells to cisplatin by targeting SRY-box transcription factor 4
title_short	MYCN contributes to the sensitization of acute myelogenous leukemia cells to cisplatin by targeting SRY-box transcription factor 4
title_full	MYCN contributes to the sensitization of acute myelogenous leukemia cells to cisplatin by targeting SRY-box transcription factor 4
title_fullStr	MYCN contributes to the sensitization of acute myelogenous leukemia cells to cisplatin by targeting SRY-box transcription factor 4
title_full_unstemmed	MYCN contributes to the sensitization of acute myelogenous leukemia cells to cisplatin by targeting SRY-box transcription factor 4
title_sort	mycn contributes to the sensitization of acute myelogenous leukemia cells to cisplatin by targeting sry-box transcription factor 4
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/f5f9fcbfe37a41d894aea6a42f012166
work_keys_str_mv	AT xianbaohuang mycncontributestothesensitizationofacutemyelogenousleukemiacellstocisplatinbytargetingsryboxtranscriptionfactor4 AT lingqi mycncontributestothesensitizationofacutemyelogenousleukemiacellstocisplatinbytargetingsryboxtranscriptionfactor4 AT weilu mycncontributestothesensitizationofacutemyelogenousleukemiacellstocisplatinbytargetingsryboxtranscriptionfactor4 AT ziyeli mycncontributestothesensitizationofacutemyelogenousleukemiacellstocisplatinbytargetingsryboxtranscriptionfactor4 AT wupingli mycncontributestothesensitizationofacutemyelogenousleukemiacellstocisplatinbytargetingsryboxtranscriptionfactor4 AT feili mycncontributestothesensitizationofacutemyelogenousleukemiacellstocisplatinbytargetingsryboxtranscriptionfactor4
_version_	1718444750870151168

MYCN contributes to the sensitization of acute myelogenous leukemia cells to cisplatin by targeting SRY-box transcription factor 4

Ejemplares similares